Efficacy and Safety of Surgical Treatment for Type IVa CBD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-14

Study Completion Date

2035-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for IVa biliary dilatation (BD). Based on this cohort, the study seeks to compare the perioperative risks, long-term outcomes, and quality of life of type IVa BD following surgical treatment, to establish standardized surgical treatment strategies for type IVa BD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biliary Dilatation National Special Disease Cohort in China

NCT06881004

Choledochal Cyst

RECRUITING

Treatment Strategy for Adult Congenital Biliary Dilation

NCT07336576

Congenital Biliary Dilation

COMPLETED

Clinical Features and Prognosis of Asymptomatic Biliary Dilatation

NCT07028164

Choledochal Cyst

COMPLETED

Host-Microbe Interactions in Biliary Dilatation

NCT07152496

Choledochal Cyst

NOT_YET_RECRUITING

Comparison of Two Kinds of Biliary Intestinal Reconstruction in Cholangiectasia

NCT03401424

Postcholecystectomy Syndrome

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Biliary dilatation (BD) is a common complex benign biliary disease. The incidence rate in Asia is one of every 1000 individuals, and the incidence rate in Europe and America is about one of every 50,000-150,000 individuals. Type IVa BD was the most commonly intrahepatic BD and the second most commonly identifiable cyst type. According to the Todani classification of congenital type IVa represents a combination of intra-and extrahepatic cystic ectasias.

However, there is still significant controversy regarding the surgical treatment approaches for this disease. Current treatment methods mainly include hepaticojejunostomy and hepatectomy. On the one hand, studies suggest that performing hepaticojejunostomy while relieving hilar bile duct stricture is sufficient. Previous research has reported that intrahepatic bile duct cysts may regress after hepaticojejunostomy. However, recent studies have described that type IV-A bile duct (BD) patients may develop long-term complications such as intrahepatic bile duct stones, anastomotic stricture, and cholangitis after hepatojejunostomy, although the specific incidence rates remain unclear. On the other hand, only a few small-series studies have reported that hepatectomy may achieve satisfactory efficacy in treating intrahepatic BD. Nevertheless, other studies have shown that 30% of patients may develop postoperative intrahepatic bile duct stones. Considering that this procedure is a higher-risk surgery compared to bilioenteric anastomosis, its effectiveness and safety in the treatment of type IVa BD introduce greater uncertainty.

This study aims at enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for IVa BDs. Based on this cohort, the study seeks to compare the perioperative risks, long-term outcomes, and quality of life of type IVa BD following surgical treatment, to establish standardized surgical treatment strategies for type IVa BD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Choledochal Cyst

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liver Resection Group

This group included patients with type IVa BD who underwent liver resection, extrahepatic bile duct resection and Roux-en-Y hepaticojejunostomy

No interventions assigned to this group

Hepaticojejunostomy Group

This group included patients with type IVa BD who underwent extrahepatic bile duct resection and Roux-en-Y hepaticojejunostomy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who have been diagnosed with Todani type IVa BD.
2. Patients aged between 0 and 80 years old, regardless of gender.
3. First-time receipt of surgery.

Exclusion Criteria

1. With abnormal intrapancreatic bile duct
2. Inappropriate Roux-loop length (outside the range of 40-60 cm for adults and 15-30 cm for children)
3. With non-relevant surgical interventions
4. Pathologically confirmed carcinogenesis
5. Unresolved choledocholithiasis, bile duct stenosis, and Intrahepatic bile duct stones during the procedure.
6. Unavailable follow-up information.

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No